KR20230170811A - 내장통 치료용 옥시코돈의 사용 - Google Patents
내장통 치료용 옥시코돈의 사용 Download PDFInfo
- Publication number
- KR20230170811A KR20230170811A KR1020237042001A KR20237042001A KR20230170811A KR 20230170811 A KR20230170811 A KR 20230170811A KR 1020237042001 A KR1020237042001 A KR 1020237042001A KR 20237042001 A KR20237042001 A KR 20237042001A KR 20230170811 A KR20230170811 A KR 20230170811A
- Authority
- KR
- South Korea
- Prior art keywords
- oxycodone
- pain
- visceral pain
- morphine
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 title claims abstract description 121
- 229960002085 oxycodone Drugs 0.000 title claims abstract description 115
- 208000009935 visceral pain Diseases 0.000 title claims abstract description 81
- 150000003839 salts Chemical class 0.000 claims abstract description 50
- 238000011282 treatment Methods 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract description 80
- 229960005181 morphine Drugs 0.000 abstract description 40
- 230000001154 acute effect Effects 0.000 abstract description 13
- 239000000730 antalgic agent Substances 0.000 abstract description 8
- 229940035676 analgesics Drugs 0.000 abstract description 7
- 229940051877 other opioids in atc Drugs 0.000 abstract description 6
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 description 63
- 230000036407 pain Effects 0.000 description 63
- 239000000203 mixture Substances 0.000 description 46
- 238000009472 formulation Methods 0.000 description 43
- 238000013268 sustained release Methods 0.000 description 28
- 239000012730 sustained-release form Substances 0.000 description 28
- 239000011159 matrix material Substances 0.000 description 25
- 238000000034 method Methods 0.000 description 24
- 229940079593 drug Drugs 0.000 description 22
- -1 alkaline earth metal salts Chemical class 0.000 description 21
- 238000013270 controlled release Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 230000000638 stimulation Effects 0.000 description 20
- 239000006186 oral dosage form Substances 0.000 description 17
- 230000000202 analgesic effect Effects 0.000 description 15
- 229940005483 opioid analgesics Drugs 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 229920000178 Acrylic resin Polymers 0.000 description 8
- 239000004925 Acrylic resin Substances 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 150000002191 fatty alcohols Chemical class 0.000 description 7
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 7
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 210000003238 esophagus Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940105606 oxycontin Drugs 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 208000000112 Myalgia Diseases 0.000 description 4
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229920003086 cellulose ether Polymers 0.000 description 4
- 229960004126 codeine Drugs 0.000 description 4
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 4
- 229960000240 hydrocodone Drugs 0.000 description 4
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 4
- 229960001410 hydromorphone Drugs 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229960005118 oxymorphone Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 4
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003405 delayed action preparation Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 208000013465 muscle pain Diseases 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- 229960003617 oxycodone hydrochloride Drugs 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229920001515 polyalkylene glycol Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 206010004663 Biliary colic Diseases 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 206010019705 Hepatic pain Diseases 0.000 description 2
- 208000007914 Labor Pain Diseases 0.000 description 2
- 208000035945 Labour pain Diseases 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010035623 Pleuritic pain Diseases 0.000 description 2
- 206010038490 Renal pain Diseases 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 238000012084 abdominal surgery Methods 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229920013820 alkyl cellulose Polymers 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 208000008384 ileus Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000005395 methacrylic acid group Chemical group 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 230000001936 parietal effect Effects 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VKNASXZDGZNEDA-UHFFFAOYSA-N 2-cyanoethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC#N VKNASXZDGZNEDA-UHFFFAOYSA-N 0.000 description 1
- SFPNZPQIIAJXGL-UHFFFAOYSA-N 2-ethoxyethyl 2-methylprop-2-enoate Chemical class CCOCCOC(=O)C(C)=C SFPNZPQIIAJXGL-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000037767 Gallbladder pain Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 159000000006 cesium salts Chemical class 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000773 effect on pain Effects 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940121367 non-opioid analgesics Drugs 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008052 pain pathway Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000006498 vasomotor response Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64549005P | 2005-01-18 | 2005-01-18 | |
| US60/645,490 | 2005-01-18 | ||
| KR1020227041445A KR20220165797A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| PCT/EP2006/050252 WO2006077212A1 (en) | 2005-01-18 | 2006-01-17 | Use of oxycodone for treating visceral pain |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227041445A Division KR20220165797A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230170811A true KR20230170811A (ko) | 2023-12-19 |
Family
ID=35871217
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237042001A Ceased KR20230170811A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020217034339A Ceased KR20210131450A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020177004572A Ceased KR20170021905A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020147018838A Ceased KR20140091782A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020077018905A Ceased KR20070100368A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020197035201A Ceased KR20190135557A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020127011713A Ceased KR20120089710A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020227041445A Ceased KR20220165797A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020087029312A Ceased KR20080106991A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020207031796A Ceased KR20200128451A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217034339A Ceased KR20210131450A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020177004572A Ceased KR20170021905A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020147018838A Ceased KR20140091782A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020077018905A Ceased KR20070100368A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020197035201A Ceased KR20190135557A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020127011713A Ceased KR20120089710A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020227041445A Ceased KR20220165797A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020087029312A Ceased KR20080106991A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
| KR1020207031796A Ceased KR20200128451A (ko) | 2005-01-18 | 2006-01-17 | 내장통 치료용 옥시코돈의 사용 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20080200493A1 (https=) |
| EP (1) | EP1838318B1 (https=) |
| JP (1) | JP5049139B2 (https=) |
| KR (10) | KR20230170811A (https=) |
| CN (1) | CN101106996B (https=) |
| AP (1) | AP2249A (https=) |
| AR (1) | AR052880A1 (https=) |
| AT (2) | ATE446092T1 (https=) |
| AU (1) | AU2006207498B2 (https=) |
| BR (1) | BRPI0606247A2 (https=) |
| CA (1) | CA2595043C (https=) |
| CY (1) | CY1109660T1 (https=) |
| DE (2) | DE602006009899D1 (https=) |
| DK (2) | DK1838318T3 (https=) |
| EA (1) | EA013544B1 (https=) |
| ES (1) | ES2333901T3 (https=) |
| HR (1) | HRP20090679T1 (https=) |
| IL (1) | IL184530A (https=) |
| ME (1) | ME01066B (https=) |
| MX (1) | MX2007007207A (https=) |
| MY (1) | MY144471A (https=) |
| NO (1) | NO338968B1 (https=) |
| NZ (1) | NZ555852A (https=) |
| PL (1) | PL1838318T3 (https=) |
| PT (1) | PT1838318E (https=) |
| RS (1) | RS51069B (https=) |
| SI (1) | SI1838318T1 (https=) |
| TW (1) | TWI432196B (https=) |
| UA (1) | UA85471C2 (https=) |
| WO (1) | WO2006077212A1 (https=) |
| ZA (1) | ZA200705231B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3069731A1 (en) | 2005-11-14 | 2016-09-21 | Labrys Biologics Inc. | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| RU2522493C2 (ru) | 2008-03-04 | 2014-07-20 | Пфайзер Лимитед | Способы лечения хронической боли |
| NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
| NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
| CN102740884A (zh) | 2009-08-28 | 2012-10-17 | 瑞纳神经科学公司 | 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法 |
| PE20141787A1 (es) | 2011-05-20 | 2014-12-07 | Alderbio Holdings Llc | Composiciones anti-cgrp y uso de las mismas |
| TWI705825B (zh) | 2011-05-20 | 2020-10-01 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）或抗降血鈣素基因相關胜肽受器（ａｎｔｉ－ｃｇｒｐ－ｒ）抗體或抗體片段治療或預防慢性及急性型腹瀉之用途 |
| CN107827982B (zh) | 2011-05-20 | 2021-07-06 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| AU2015230933B2 (en) | 2014-03-21 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| CN109952314A (zh) | 2016-09-23 | 2019-06-28 | 泰瓦制药国际有限公司 | 治疗难治性偏头痛 |
| CA3115122A1 (en) | 2018-11-19 | 2020-05-28 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
| WO2020146527A1 (en) | 2019-01-08 | 2020-07-16 | Alder Biopharmaceuticals, Inc. | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
| CA3077973A1 (en) | 2020-04-06 | 2021-10-06 | H. Lundbeck A/S | Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656295A (en) * | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| UA48219C2 (uk) * | 1996-03-25 | 2002-08-15 | Елі Ліллі Енд Компані | Композиція для вгамування болю (варіанти) та спосіб вгамування болю |
| UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| US6992193B2 (en) * | 2003-06-10 | 2006-01-31 | Adolor Corporation | Sulfonylamino phenylacetamide derivatives and methods of their use |
-
2006
- 2006-01-05 TW TW095100458A patent/TWI432196B/zh not_active IP Right Cessation
- 2006-01-09 MY MYPI20060082A patent/MY144471A/en unknown
- 2006-01-17 EA EA200701541A patent/EA013544B1/ru not_active IP Right Cessation
- 2006-01-17 KR KR1020237042001A patent/KR20230170811A/ko not_active Ceased
- 2006-01-17 ES ES06700652T patent/ES2333901T3/es not_active Expired - Lifetime
- 2006-01-17 KR KR1020217034339A patent/KR20210131450A/ko not_active Ceased
- 2006-01-17 DE DE602006009899T patent/DE602006009899D1/de not_active Expired - Lifetime
- 2006-01-17 KR KR1020177004572A patent/KR20170021905A/ko not_active Ceased
- 2006-01-17 CA CA2595043A patent/CA2595043C/en not_active Expired - Lifetime
- 2006-01-17 EP EP06700652A patent/EP1838318B1/en not_active Expired - Lifetime
- 2006-01-17 KR KR1020147018838A patent/KR20140091782A/ko not_active Ceased
- 2006-01-17 JP JP2007550797A patent/JP5049139B2/ja not_active Expired - Fee Related
- 2006-01-17 KR KR1020077018905A patent/KR20070100368A/ko not_active Ceased
- 2006-01-17 US US11/814,020 patent/US20080200493A1/en not_active Abandoned
- 2006-01-17 BR BRPI0606247-4A patent/BRPI0606247A2/pt not_active Application Discontinuation
- 2006-01-17 KR KR1020197035201A patent/KR20190135557A/ko not_active Ceased
- 2006-01-17 KR KR1020127011713A patent/KR20120089710A/ko not_active Ceased
- 2006-01-17 PT PT06700652T patent/PT1838318E/pt unknown
- 2006-01-17 PL PL06700652T patent/PL1838318T3/pl unknown
- 2006-01-17 DK DK06700652T patent/DK1838318T3/da active
- 2006-01-17 KR KR1020227041445A patent/KR20220165797A/ko not_active Ceased
- 2006-01-17 KR KR1020087029312A patent/KR20080106991A/ko not_active Ceased
- 2006-01-17 AP AP2007004057A patent/AP2249A/xx active
- 2006-01-17 HR HR20090679T patent/HRP20090679T1/hr unknown
- 2006-01-17 SI SI200630538T patent/SI1838318T1/sl unknown
- 2006-01-17 DE DE202006019887U patent/DE202006019887U1/de not_active Expired - Lifetime
- 2006-01-17 WO PCT/EP2006/050252 patent/WO2006077212A1/en not_active Ceased
- 2006-01-17 ME MEP-2009-352A patent/ME01066B/me unknown
- 2006-01-17 UA UAA200708142A patent/UA85471C2/ru unknown
- 2006-01-17 AT AT06700652T patent/ATE446092T1/de active
- 2006-01-17 AU AU2006207498A patent/AU2006207498B2/en not_active Expired
- 2006-01-17 KR KR1020207031796A patent/KR20200128451A/ko not_active Ceased
- 2006-01-17 RS RSP-2009/0553A patent/RS51069B/sr unknown
- 2006-01-17 MX MX2007007207A patent/MX2007007207A/es active IP Right Grant
- 2006-01-17 NZ NZ555852A patent/NZ555852A/en unknown
- 2006-01-17 CN CN2006800024739A patent/CN101106996B/zh not_active Expired - Lifetime
- 2006-01-18 AR ARP060100177A patent/AR052880A1/es unknown
-
2007
- 2007-03-09 AT AT0014807U patent/AT9895U1/de not_active IP Right Cessation
- 2007-07-02 ZA ZA200705231A patent/ZA200705231B/xx unknown
- 2007-07-10 IL IL184530A patent/IL184530A/en active IP Right Grant
- 2007-07-24 DK DK200700207U patent/DK200700207U3/da not_active IP Right Cessation
- 2007-08-14 NO NO20074174A patent/NO338968B1/no not_active IP Right Cessation
-
2009
- 2009-12-16 CY CY20091101308T patent/CY1109660T1/el unknown
-
2014
- 2014-10-15 US US14/515,216 patent/US9271974B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9271974B2 (en) | Use of oxycodone for treating visceral pain | |
| KR20070107805A (ko) | 옥시코돈 및 날록손 함유 제형 | |
| TW200900054A (en) | Sustained release oral dosage forms of a prodrug of R-baclofen and methods of treatment | |
| JP6137833B2 (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| AU2007201808A8 (en) | A method for alleviating signs and symptoms of spasticity | |
| BRPI0621633A2 (pt) | composição farmacêutica, método para tratar distúrbio de déficit de atenção por hiperatividade (adhd) e composição farmacêutica de liberação sustentada | |
| KR20250145673A (ko) | 통증 완화에 유용한 요법 및 조성물 | |
| HK1107933B (en) | Use of oxycodone for treating visceral pain | |
| AU2015234576A1 (en) | Reducing drug liking in a subject |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20231205 Application number text: 1020227041445 Filing date: 20221125 |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20241126 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20250206 Comment text: Decision to Refuse Application Patent event code: PE06012S01D |